Company news

Jade Biosciences, Inc. news in 2025

Jade Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Jade Biosciences Announces $45 Million Private Placement

December 15, 2025

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

November 8, 2025

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

October 7, 2025

Jade Biosciences Announces $135 Million Private Placement

October 7, 2025

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

September 2, 2025

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

Jade Biosciences to Participate in Two Upcoming Investor Conferences

July 8, 2025

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

July 1, 2025

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

June 9, 2025

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

June 2, 2025

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

April 20, 2025

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

April 8, 2025

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

April 6, 2025

Decks in 2025